Lumbar disc pain one year after stem cell therapy by Dr Harry Adelson
Lisa describes her outcome one year after having bone marrow stem cells injected into her degenerated and dehydrated lumbar discs by Dr Harry Adelson http://www.doc...
By: Harry Adelson, N.D.
Here is the original post:
Lumbar disc pain one year after stem cell therapy by Dr Harry Adelson - Video
ReNeuron Group Quote more
Price: 2.85
Chg: -0.17
Chg %: -5.47%
Date: 12:02
Stem cell treatment developer ReNeuron lost an increased 7.1m in a "transformational" year to end-March but still had plenty of cash in the bank as it moves into new cell manufacturing facility and files an investigational new drug (IND) application in the US early next year.
The AIM-listed company held cash outflow from operating activities roughly flat at 6m over the period, leaving cash, cash equivalents and bank deposits at period end of 20.92m, thanks to the 23.44m net fundraising in August 2013.
Chairman Bryan Morton said it was a transformational year for the business, both operationally and financially, as its lead stem cell therapy candidate for stroke entered Phase II clinical trials and the company began clinical development of a candidate for critical limb ischaemia.
He also noted that in both cases, and earlier-than-planned, ReNeuron gained regulatory approval to use a cryopreserved variant of its lead 'CTX' stem cell product line, which gives the treatments the potential to have "significant commercial and competitive advantages".
He confirmed the move to new cell manufacturing facility in South Wales early next year was on track, "which we believe will become a major element of ReNeurons overall value proposition".
Follow this link:
ReNeuron well set after 'transformational' year
KANSAS CITY, KS (KCTV) -
A KCK company is developing a stem cell treatment to help dogs deal with crippling pain from arthritis.
Aratana Therapeutics is working to treat osteoarthritis in pets via the stem cell treatment.
If the U.S. Food and Drug Administration approves, it would be the first treatment of its kind.
The treatment wouldn't provide a cure but would give much-needed relief.
"They're still able to move better but they can't do the things they did when they were younger," dog owner Rachel Thieme said.
Osteoarthritis can be quite debilitating for canines.
"It's really tough because may be there are other areas of quality of life that are fine. They are eating fine. They have that motivation but they just can't physically do anything, so sometimes you have to euthanize them," Thieme said.
The only way to cure the condition is to conduct a total joint replacement.
But the stem cell procedure hopefully will reduce the need for medications and therapies, said Kara Forsee, a veterinary surgeon for BluePearl Veterinary Partners.
See original here:
KC area company developing stem cell treatments for pooches
Scientists copied processes that occur in the womb to create eye tissue Study used adult stem cells that have been genetically reprogrammed Lab-grown tissue responded to light the same way as it does in the eye The study represents a first step towards restoring sight in the blind
By Ellie Zolfagharifard
Published: 12:14 EST, 10 June 2014 | Updated: 14:02 EST, 10 June 2014
688 shares
5
View comments
A light-sensitive 'eye-in-a-dish' has been created by scientists using a type of human stem cell.
The three dimensional structure represents a first step towards restoring sight to the blind, say the researchers.
Processes that occur in the womb were copied to create complex retinal tissue in a laboratory petri dish.
A light-sensitive 'eye-in-a-dish' has been created by scientists in Maryland. The three dimensional structure represents a first step towards restoring sight to the blind, say the researchers. Pictured are the photoreceptors (in green) within a 'mini retina' structure (blue) that was created using human stem cells
Read more:
Scientists create an 'eye-in-a-dish' using human stem cells
Beverly Hills, CA (PRWEB) June 16, 2014
The top stem cell doctors at Beverly Hills Orthopedic Institute are now offering regenerative medicine procedures for Achilles tendonitis and tears. The procedures include options for several types of stem cell procedures that can provide pain relief and help patients avoid surgery. Call (310) 438-5343 for more information and scheduling.
Achilles tendonitis or tears may bother patients for many months and not respond well to traditional treatments. This may include NSAIDS, bracing and steroid injections. While surgery for these conditions may be extremely successful, there is often a considerable rehabilitation and potential surgery complications.
Stem cell injections for Achilles tears or tendonitis have been a revolutionary treatment. This may include bone marrow derived injections, or amniotic derived stem cell procedures. Both offer exceptional concentrations of stem cells, growth factors and additional reparative materials.
The procedures are performed as an outpatient, with the amniotic derived material coming from consenting donors after scheduled c-sections. There is no fetal material used, negating any ethical concerns.
Dr. Raj at Beverly Hills Orthopedic Institute is a Double Board Certified orthopedic doctor. He treats patients from weekend warriors to amateur and professional athletes, along with celebrities, executives, manual laborers and grandparents.
For more information and scheduling, call (310) 438-5343.
Follow this link:
Stem Cell Doctor at Beverly Hills Orthopedic Institute Now Offering Regenerative Procedures for Achilles Tendonitis ...
Background
Relapsed multiple myeloma has no standard treatment, and the role of autologous stem-cell transplantation (ASCT) has not been fully defined. We aimed to compare high-dose melphalan plus salvage ASCT with cyclophosphamide in patients with relapsed multiple myeloma who had previously undergone ASCT.
Between April 16, 2008, and Nov 19, 2012, 297 patients were registered, of whom 293 received PAD re-induction therapy. Between Aug 26, 2008, and Nov 16, 2012, 174 patients with sufficient PBSCs were randomised to salvage ASCT (n=89) or cyclophosphamide (n=85). After a median follow-up of 31 months (IQR 1942), median time to progression was significantly longer in the salvage ASCT than in the cyclophosphamide group (19 months [95% CI 1625] vs 11 months [912]; hazard ratio 036 [95% CI 025053]; p<00001). Frequently reported (in >10% of patients) grade 34 adverse events with PAD induction, salvage ASCT, and cyclophosphamide were: neutropenia (125 [43%] of 293 patients after PAD, and 63 [76%] of 83 patients in the salvage ASCT group vs 11 [13%] of 84 patients in the cyclophosphamide group), thrombocytopenia (150 [51%] after PAD, and 60 [72%] vs four [5%], respectively), and peripheral neuropathy (35 [12%] after PAD, and none vs none, respectively).
This study provides evidence for the improved efficacy of high-dose melphalan plus salvage ASCT when compared with cyclophosphamide in patients with relapsed multiple myeloma eligible for intensive therapy, which might help to guide clinical decisions regarding the management of such patients.
Read the original here:
Systematic review
KANSAS CITY, KS (KCTV) -
A KCK company is developing a stem cell treatment to help dogs deal with crippling pain from arthritis.
Aratana Therapeutics is working to treat osteoarthritis in pets via the stem cell treatment.
If the U.S. Food and Drug Administration approves, it would be the first treatment of its kind.
The treatment wouldn't provide a cure but would give much-needed relief.
"They're still able to move better but they can't do the things they did when they were younger," dog owner Rachel Thieme said.
Osteoarthritis can be quite debilitating for canines.
"It's really tough because may be there are other areas of quality of life that are fine. They are eating fine. They have that motivation but they just can't physically do anything, so sometimes you have to euthanize them," Thieme said.
The only way to cure the condition is to conduct a total joint replacement.
But the stem cell procedure hopefully will reduce the need for medications and therapies, said Kara Forsee, a veterinary surgeon for BluePearl Veterinary Partners.
Read the original here:
KC area company developing stem cell treatments for pooches - Tucson News Now
LOS ANGELES (KABC) --
Amanda Canale doesn't take time with her daughter and niece for granted. She's just happy to feel good.
"I've been in the hospital, and I've been sick my whole life," Amanda said.
Amanda was born with a rare blood disorder that required daily shots.
"Basically, I have no white blood cells," Amanda said. "I have no immune system at all."
At 23, she developed leukemia and was given two weeks to live. She desperately needed a bone marrow transplant, but family members weren't matches. Her doctor suggested an umbilical cord blood transplant.
"The cord was a perfect match and it was available, so it was the right solution for her," Edward Agura, MD, Medical Director of Bone Marrow Transplantation, Baylor University Medical Center, Dallas, said.
Cord blood contains stem cells that regenerate. Mothers of newborns can save their child's own blood or donate it. More than 30,000 transplants have been performed worldwide. However, because the blood comes from a tiny newborn, there's not much of it.
"The cord blood is rare, precious and few, and yet is more potent in its ability to grow," Dr. Agura said.
Now, doctors at Baylor are treating patients by combining cord blood from multiple donors. They've found this increases the number of stem cells and provides faster recovery. Amanda's transfusion was from a baby whose mother donated six years earlier. The procedure completely cured her cancer and blood disorder.
Originally posted here:
Cord blood infusion saves woman's life
SOURCE: Endonovo Therapeutics, Inc.
Dr. Leonard Makowka, a Leading Authority in Hepatic Science, Joins Endonovo Therapeutics as Its Chief Medical Officer
LOS ANGELES, CA--(Marketwired - Jun 11, 2014) - Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a biotechnology company developing innovative regenerative therapies, announced today that it has created technologies to pursue the development and manufacturing of next generation regenerative products that no longer require the administration of stem cells. Endonovo's "Cell Free" products will harness the biological molecules secreted by cells to create truly "off-the-shelf" therapeutics that can be delivered to patients in a much timelier manner than is possible with autologous and allogeneic stem cell therapies.
There are currently more than 300 mesenchymal stem cell clinical trials underway to treat a wide range of pathological conditions listed on the ClinicalTrials.gov database. These clinical trials are still based on the transplantation of mesenchymal stem cells. Endonovo is developing therapies that may mitigate many of the current drawbacks of cell-based therapies, such as the low survival and engraftment rate of transplanted stem cells, the risk of occlusion in microvasculature, and unregulated growth, such as hyper-innervation or ossification and/or calcification in the body.
"Cell Free" regenerative products may also mitigate many of the limitations to the commercialization of stem cell therapies, such as the manufacturing, storage and delivery of viable cells. "Cell Free" regenerative products are commercially more attractive because they are simpler to manufacture, easier to store and maintain their therapeutic potency for longer periods of time when compared to stem cells.
Additionally, Endonovo Therapeutics announced that it has appointed Dr. Leonard Makowka, M.D., Ph.D., to serve as the Company's Chief Medical Officer. Dr. Makowka was formerly the Chairman of the Department of Surgery and Director of Transplantation Services at Cedars Sinai Medical Center in Los Angeles, CA, and served as Professor of Surgery at the UCLA School of Medicine. He was also Executive Director of the Comprehensive Liver Disease Center, which used a multiple disciplinary approach to the treatment of liver disease, at St. Vincent's Medical Center in Los Angeles, CA. He has published over 400 articles and chapters in both clinical and basic scientific research and has been regarded as a leading authority in hepatic science. Dr. Makowka has also served as a board member of various public and private healthcare and life science companies.
"We are very pleased to welcome Dr. Makowka to the Endonovo team," said Endonovo Therapeutics CEO, Alan Collier. "His experience and expertise will be a tremendous asset in the development of 'cell-free' therapeutics that can promote the regeneration of tissues without the need to inject stem cells into the body, which would result in safer, more effective therapies, lower costs and the saving of lives."
"I am excited to join Endonovo Therapeutics and help the company develop its 'cell-free' therapeutic platform," stated Dr. Leonard Makowka, Chief Medical Officer at Endonovo Therapeutics. "Although it is early in the developmental lifecycle, we are excited about the development of first-in-class, 'cell free' regenerative products that can protect and stimulate the regeneration of tissues. These products would be truly 'off-the-shelf' therapies that could be quickly administered following organ injuries, such as a heart attack, a stroke, acute and/or chronic liver disease and the 'aging' of organs, in order to protect the organ and begin healing it."
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a publicly traded biotechnology company developing off-the-shelf, cell free regenerative products and non-invasive, bioelectronic therapies designed to extend and enhance the human life by regenerating tissues and organs that have become injured or damaged due to disease and age. The Company is developing therapies for various inflammatory, autoimmune and degenerative diseases using biomolecules secreted from cells and Time-Varying Electromagnetic Fields (TVEMF).
More:
Endonovo Therapeutics to Develop Next Generation, Off-The-Shelf, Cell Free Regenerative Products
LOS ANGELES (KABC) --
Amanda Canale doesn't take time with her daughter and niece for granted. She's just happy to feel good.
"I've been in the hospital, and I've been sick my whole life," Amanda said.
Amanda was born with a rare blood disorder that required daily shots.
"Basically, I have no white blood cells," Amanda said. "I have no immune system at all."
At 23, she developed leukemia and was given two weeks to live. She desperately needed a bone marrow transplant, but family members weren't matches. Her doctor suggested an umbilical cord blood transplant.
"The cord was a perfect match and it was available, so it was the right solution for her," Edward Agura, MD, Medical Director of Bone Marrow Transplantation, Baylor University Medical Center, Dallas, said.
Cord blood contains stem cells that regenerate. Mothers of newborns can save their child's own blood or donate it. More than 30,000 transplants have been performed worldwide. However, because the blood comes from a tiny newborn, there's not much of it.
"The cord blood is rare, precious and few, and yet is more potent in its ability to grow," Dr. Agura said.
Now, doctors at Baylor are treating patients by combining cord blood from multiple donors. They've found this increases the number of stem cells and provides faster recovery. Amanda's transfusion was from a baby whose mother donated six years earlier. The procedure completely cured her cancer and blood disorder.
See the rest here:
Umbilical cord transplants saving lives